Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Melanoma 10Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Mesothelioma 2Carcinoma, Transitional Cell 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Germ Cell Tumor 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Recurrence 1Neoplasms, Unknown Primary 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Immunoblastic Lymphadenopathy 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Anus Neoplasms 1Adenocarcinoma of Lung 1

Interventions

fludarabine phosphate 23Peripheral Blood Stem Cell Transplantation 23Cyclophosphamide 20Whole-Body Irradiation 18Mycophenolic Acid 16Cyclosporine 15Etoposide 11Tacrolimus 10Busulfan 10Antilymphocyte Serum 10Methotrexate 9Melphalan 9Bortezomib 9Vorinostat 6Rituximab 6Filgrastim 6Doxorubicin 6Vincristine 5Therapeutics 5Prednisone 5Lenalidomide 5tanespimycin 4Sirolimus 4Radiotherapy 4Psychiatric Rehabilitation 4Methylprednisolone 4Everolimus 4Carboplatin 4pembrolizumab 3Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × tislelizumab × Dermatologic × Clear all
NCT03493451 2024-10-26

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

BeiGene

Phase 2 Completed
77 enrolled 20 charts
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡